AIM ImmunoTech, Inc. (AIM)
0.2297
0.00 (0.00%)
USD |
NYAM |
Sep 08, 16:00
0.2297
0.00 (0.00%)
Pre-Market: 09:09
AIM ImmunoTech Gross Profit Margin (Quarterly) : -1.95K% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.95K% |
| March 31, 2026 | -113.6% |
| December 31, 2025 | -295.2% |
| September 30, 2025 | -369.2% |
| June 30, 2025 | -160.0% |
| March 31, 2025 | -325.0% |
| December 31, 2024 | -57.78% |
| September 30, 2024 | -102.9% |
| June 30, 2024 | -38.00% |
| March 31, 2024 | -65.00% |
| December 31, 2023 | -7.69% |
| September 30, 2023 | -80.43% |
| June 30, 2023 | -116.7% |
| March 31, 2023 | -71.43% |
| December 31, 2022 | -269.6% |
| September 30, 2022 | -142.9% |
| June 30, 2022 | -130.0% |
| March 31, 2022 | -133.3% |
| December 31, 2021 | -441.0% |
| September 30, 2021 | -662.1% |
| June 30, 2021 | -1.11K% |
| March 31, 2021 | -1.17K% |
| December 31, 2020 | -610.7% |
| September 30, 2020 | -466.7% |
| June 30, 2020 | -446.2% |
| Date | Value |
|---|---|
| March 31, 2020 | -788.9% |
| December 31, 2019 | -334.0% |
| September 30, 2019 | -277.0% |
| June 30, 2019 | -641.4% |
| March 31, 2019 | |
| December 31, 2018 | -17.50% |
| September 30, 2018 | -750.0% |
| June 30, 2018 | -831.8% |
| March 31, 2018 | -477.7% |
| December 31, 2017 | -492.0% |
| September 30, 2017 | -343.3% |
| June 30, 2017 | -60.33% |
| March 31, 2017 | -384.5% |
| December 31, 2016 | -2.65K% |
| September 30, 2016 | -1.89K% |
| June 30, 2016 | -3.09K% |
| March 31, 2016 | -1.09K% |
| December 31, 2015 | -1.26K% |
| September 30, 2015 | -1.43K% |
| June 30, 2015 | -978.7% |
| March 31, 2015 | -933.3% |
| December 31, 2014 | -720.0% |
| September 30, 2014 | -920.0% |
| June 30, 2014 | -716.7% |
| March 31, 2014 | -543.4% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.82% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -194.3% |
| Return on Invested Capital | -1.19K% |
| Profit Margin (Quarterly) | -14.57K% |
| Operating Margin (Quarterly) | -13.42K% |
| Return on Net Operating Assets | -620.9% |